Multiple Myeloma Day

Multiple Myeloma Day

Mar 29, 2019

multiple myeloma day
Multiple Myeloma Day

Multiple Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers. For more information on  Multiple Myeloma.

Downloads

Article in PDF

Recent Articles
  1. Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
  2. AZ offloads; Pfizer’s deal; Takeda’s work on plant; Germany’s doc payment
  3. Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVY...
  4. Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian C...
  5. Leo Pharma’s Hand Eczema Clinical Trial Updates; GSK’s PD-1 inhibitor Jemperli Approval; Ro...
pharma-news-for-ucb-brainxell-metsera
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Intensity Therapeutics Publishes Compelling Clinical Data for INT230-6 in Advanced Cancers; UCB Wins FDA Approval for KYGEVVI for Rare Mitochondrial Disease TK2d; BrainXell Therapeutics Unveils Promising Preclinical Data for iPSC-Derived Neuronal Therapy in Parkinson’s Disease; CARsgen Therapeutics Reports Encouraging Clinical Data for Allogeneic CAR-T Products in Hematologic Malignancies; Novo Nordisk’s $9 Billion Counterbid for Metsera Ignites Landmark Obesity Drug Market Battle

pharma-news-for-novartis-gsk-syndax
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Syndax Pharmaceuticals Receives FDA Approval for REVUFORJ; FDA Approves BLENREP for Adults with Relapsed/Refractory Multiple Myeloma; Novartis to Acquire Avidity for $12 Billion; BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study; Eli Lilly to Acquire Adverum Biotechnologies

pharma-news-for-merck-incyte-biocon
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Merck Wins FDA Approval for KEYTRUDA QLEX for Subcutaneous Use in Adults With Solid Tumors; Incyte Gains FDA Nod for OPZELURA Cream in Children Aged 2–11 With Atopic Dermatitis; Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome; MavriX Bio Secures FDA Fast Track for MVX-220 Gene Therapy in Angelman Syndrome; Biocon Biologics Gets FDA Approval for Denosumab Biosimilars BOSAYA and AUKELSO

Multiple Myeloma
Multiple MYELOMA drugs Market.
Multiple Myeloma Market
Multiple Myeloma Pipeline
RBC
red blood cells
loader
loader